Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...
Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback